CICC Research Forecasts Strong Price Appreciation for Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company (NYSE:LLY) had its target price lifted by analysts at CICC Research from $801.00 to $1,060.00 in a research note issued to investors on Thursday,MarketScreener reports. The brokerage presently has a “neutral” rating on the stock. CICC Research’s price objective suggests a potential upside of 3.45% from the company’s current price.

Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Loop Capital set a $950.00 target price on Eli Lilly and Company in a report on Monday. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,015.11.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $1.80 during trading on Thursday, hitting $1,024.67. The stock had a trading volume of 3,859,587 shares, compared to its average volume of 4,072,967. The stock’s 50 day moving average is $826.89 and its two-hundred day moving average is $780.87. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,033.62. The stock has a market cap of $968.70 billion, a price-to-earnings ratio of 66.97, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently modified their holdings of LLY. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. increased its stake in Eli Lilly and Company by 1.2% during the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 1,710 shares of the company’s stock worth $1,305,000 after purchasing an additional 20 shares in the last quarter. Warther Private Wealth LLC increased its stake in shares of Eli Lilly and Company by 734.6% in the 3rd quarter. Warther Private Wealth LLC now owns 22,101 shares of the company’s stock valued at $16,863,000 after purchasing an additional 19,453 shares during the last quarter. Creative Planning grew its holdings in shares of Eli Lilly and Company by 32.2% during the third quarter. Creative Planning now owns 353,081 shares of the company’s stock worth $269,401,000 after purchasing an additional 86,089 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in Eli Lilly and Company by 6.5% in the third quarter. Lazard Asset Management LLC now owns 1,083,948 shares of the company’s stock valued at $826,650,000 after buying an additional 66,050 shares during the period. Finally, AQR Capital Management LLC raised its stake in Eli Lilly and Company by 30.0% during the 3rd quarter. AQR Capital Management LLC now owns 451,182 shares of the company’s stock worth $330,825,000 after buying an additional 104,207 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.